412 related articles for article (PubMed ID: 15959774)
21. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer.
Battaglia A; Buzzonetti A; Baranello C; Ferrandina G; Martinelli E; Fanfani F; Scambia G; Fattorossi A
Cancer Immunol Immunother; 2009 Sep; 58(9):1363-73. PubMed ID: 19172271
[TBL] [Abstract][Full Text] [Related]
22. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
[TBL] [Abstract][Full Text] [Related]
23. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
Badoual C; Hans S; Rodriguez J; Peyrard S; Klein C; Agueznay Nel H; Mosseri V; Laccourreye O; Bruneval P; Fridman WH; Brasnu DF; Tartour E
Clin Cancer Res; 2006 Jan; 12(2):465-72. PubMed ID: 16428488
[TBL] [Abstract][Full Text] [Related]
25. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
26. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
27. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma.
Grabenbauer GG; Lahmer G; Distel L; Niedobitek G
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3355-60. PubMed ID: 16740757
[TBL] [Abstract][Full Text] [Related]
28. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
29. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
30. Hyperthermia and irradiation of head and neck squamous cancer cells causes migratory profile changes of tumour infiltrating lymphocytes.
Schmidtner J; Distel LV; Ott OJ; Nkenke E; Sprung CN; Fietkau R; Lubgan D
Int J Hyperthermia; 2009 Aug; 25(5):347-54. PubMed ID: 19479600
[TBL] [Abstract][Full Text] [Related]
31. Use of CFSE to monitor ex vivo regulatory T-cell suppression of CD4+ and CD8+ T-cell proliferation within unseparated mononuclear cells from malignant and non-malignant human lymph node biopsies.
Hilchey SP; Bernstein SH
Immunol Invest; 2007; 36(5-6):629-48. PubMed ID: 18161522
[TBL] [Abstract][Full Text] [Related]
32. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
[TBL] [Abstract][Full Text] [Related]
33. The significance of Treg cells in defective tumor immunity.
Kosmaczewska A; Ciszak L; Potoczek S; Frydecka I
Arch Immunol Ther Exp (Warsz); 2008; 56(3):181-91. PubMed ID: 18512029
[TBL] [Abstract][Full Text] [Related]
34. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment.
Bergmann C; Strauss L; Zeidler R; Lang S; Whiteside TL
Cancer Immunol Immunother; 2007 Sep; 56(9):1429-42. PubMed ID: 17265021
[TBL] [Abstract][Full Text] [Related]
35. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
36. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
37. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment.
Gasparoto TH; de Souza Malaspina TS; Benevides L; de Melo EJ; Costa MR; Damante JH; Ikoma MR; Garlet GP; Cavassani KA; da Silva JS; Campanelli AP
Cancer Immunol Immunother; 2010 Jun; 59(6):819-28. PubMed ID: 20012605
[TBL] [Abstract][Full Text] [Related]
38. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
39. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
Chikamatsu K; Albers A; Stanson J; Kwok WW; Appella E; Whiteside TL; DeLeo AB
Cancer Res; 2003 Jul; 63(13):3675-81. PubMed ID: 12839958
[TBL] [Abstract][Full Text] [Related]
40. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
Petersen RP; Campa MJ; Sperlazza J; Conlon D; Joshi MB; Harpole DH; Patz EF
Cancer; 2006 Dec; 107(12):2866-72. PubMed ID: 17099880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
